6505--Glipizide Tablets
Closed Pre-Solicitation Posted
- Solicitation number
- 36E79726R0031_1
- Agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Veterans Affairs National Acquisition Center intends to solicit a Request for Proposal (Solicitation 36E79726R0031) for Glipizide Tablets, an unrestricted procurement, with an offer due date of October 8, 2026. The solicitation will be issued in FAR Part 12 commercial item format and will award one contract to supply the VA (including Consolidated Mail Order Pharmacies and Option 2 State Veterans Homes), Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center.
The contract period runs for one year plus four pre-priced one-year option periods, with estimated annual demand ranging from approximately 18,238 to 88,612 bottles depending on line item, totaling approximately 407,952 bottles across all seven line items annually. Glipizide tablets are offered in two strengths (5mg and 10mg) in unit-of-use packaging of 90, 180, 360, 500, and 1,000-count bottles.
Offerors must supply product under a unique 11-digit National Drug Code (NDC) with their own label as the sole label on packaging; VA labels will adhere over the contractor's label. Bottles must be cylindrical with minimum 120cc volume and 5.75-inch circumference, with safety-caps capable of deshelling or conversion to non-safety caps, and accommodate a 5.25 x 2-inch label plus 0.5-inch additional space for barcode and expiration/lot number visibility. Contractors must demonstrate current FDA good manufacturing practice (cGMP) acceptance, hold GS1-128 or HIBCC bar coding, comply with Drug Supply Chain Security Act (DSCSA) requirements, and maintain business-to-business agreements with Government Prime Vendors (McKesson for VA; McKesson, Cencora, Cardinal Health, and DMS Pharmaceutical Group for DoD). Distributors must provide a Letter of Commitment from the manufacturer. Pricing must include a 0.5% Cost Recovery Fee and shall not exceed two decimal places. Products must be delivered within a maximum 60-calendar-day implementation period. Backorders must be reported within four calendar days and resolved within 15 calendar days.
Small business subcontracting plan requirements apply for contracts exceeding $900,000.
Notice text
PRE-SOLICITATION NOTICE: The VA National Acquisition Center intends to issue a Request for Proposal (RFP) 36E79726R0031 for an unrestricted procurement for Glipizide Tablets, for the Department of Veterans Affairs (VA) (inclusive of Consolidated Mail Order Pharmacies (CMOPs) and Option 2 State Veterans Homes (SVH)), Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC).
VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted items. The contract period will be for one year plus four pre-priced one-year option periods. The contract items will be distributed through the VA s and DoD s respective Pharmaceutical Prime Vendor Programs.
Offerors must state the exact name (name that appears on label) by which the drug will be supplied and have an NDC number that is unique to the offeror. The successful offeror/contractor's label with its unique NDC shall be the only label on the product. Contractors shall not affix their label over another label on the product. VA labels must be able to securely adhere over the successful offeror/contractor's label.
This product requires unit of use packaging, as identified in the Schedule of Supplies (e.g., 90, 180, and 360 count bottles). The bottles shall contain a safety-cap capable of having the outer part of the cap deshelled and/or a convertible cap to produce a non-safety cap and a bottle with a minimum required size of 120cc volume. The safety cap must not exceed the diameter of the bottle. The bottle must have a cylindrical body and minimum of 5.75 circumference. The bottle must fit a label with a dimension of 5.25 x 2 . The 0.5 additional space is required to keep the bar code exposed and/or allow for the display of the expiration date and lot number.
Solicitation #36E79726R0031 will be electronically issued in commercial item format in accordance with FAR Part 12 on or about July 27, 2026, with a tentative closing date of August 10, 2026. The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at SAM.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check Contracting Opportunities at SAM.gov for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Deb Fassl. Questions can be e-mailed to Deborah.Fassl@va.gov.
The estimated annual requirements are as follows:
REQUIREMENT DESCRIPTION
ITEM
DESCRIPTION
UNIT
of
USE
PKG. SIZE
(Tablets
per Bottle)
TOTAL EST. ANNUAL USAGE
(Bottles)
1
GLIPIZIDE 5MG TAB
Y
90
60,691
2
GLIPIZIDE 5MG TAB
Y
180
58,708
3a
GLIPIZIDE 5MG TAB
N
500
50,084
OR
3b
GLIPIZIDE 5MG TAB
N
1000
25,042
4
GLIPIZIDE 10MG TAB
Y
90
26,156
5
GLIPIZIDE 10MG TAB
Y
180
88,612
6
GLIPIZIDE 10MG TAB
Y
360
18,238
7a
GLIPIZIDE 10MG TAB
N
500
57,870
OR
7b
GLIPIZIDE 10MG TAB
N
1000
28,935
Files
| File | Type | Posted |
|---|---|---|
| 36E79726R0031 0001.docx | DOCX document | |
| RFP 36E79726R0031 - Glipizide Tablets.docx | DOCX document | |
| Subcontracting Plan Template 08.2026.pdf | ||
| 36E79726R0031_1.docx | DOCX document |
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Pre-Solicitation | |
| 6505--Glipizide Tablets | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| 6505--Imatinib Tablets | National Acquisition Center | No set-aside | |
| 6505--Prednisolone 1% Ophthalmic Solution | National Acquisition Center | No set-aside | |
| 6505--Latanoprost Ophthalmic Solution (VA-27-00006027) | National Acquisition Center | No set-aside | |
| Febuxostat Tablets | Medical Supply Chain | No set-aside | |
| Epinephrine Injector | Medical Supply Chain | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity